Absence of Four-and-a-Half LIM domain protein 2 decreases atherosclerosis in ApoE-/- Mice

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 35, Issue 5, 2015, Pages 1190-1197

  Ebrahimian, Talin ^a   Simon, David ^a   Lemarié, Catherine A ^a   Simeone, Stefania ^a   Heidari, Maryam ^a   Mann, Koren K ^a   Wassmann, Sven ^a   Lehoux, Stephanie ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

atherosclerosis; cell adhesion molecules; chemokines; FHL2 protein, mouse; monocytes

Indexed keywords

APOLIPOPROTEIN E; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CXCR2; CHOLESTEROL; COLLAGEN; CXCL1 CHEMOKINE; FOUR AND A HALF LIM DOMAIN PROTEIN 2; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 1BETA; LIM PROTEIN; LOW DENSITY LIPOPROTEIN; MESSENGER RNA; RANTES; THIOGLYCOLIC ACID; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; CELL ADHESION MOLECULE; CHEMOKINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; AORTA SINUS; APOPTOSIS; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BONE MARROW; BONE MARROW CELL; BRACHIOCEPHALIC TRUNK; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENDOTHELIUM CELL; GENE EXPRESSION; INFLAMMATION; LEUKOCYTE FUNCTION; LIPID DIET; MACROPHAGE; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; SMOOTH MUSCLE FIBER; ANIMAL; CELL CULTURE; COMPARATIVE STUDY; DEFICIENCY; DISEASE MODEL; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; RANDOMIZATION;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CELL ADHESION MOLECULES; CELLS, CULTURED; CHEMOKINES; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; INTERCELLULAR ADHESION MOLECULE-1; LIM DOMAIN PROTEINS; MACROPHAGES; MICE; MICE, KNOCKOUT; MYELOID CELLS; RANDOM ALLOCATION;

EID: 84933054071     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.114.305071     Document Type: Article

References (40)

1. Hansson GK, Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005 352 1685 1695. doi: 10.1056/NEJMra043430
2. Libby P, Inflammation in atherosclerosis. Nature 2002 420 868 874. doi: 10.1038/nature01323
3. Geissmann F, Jung S, Littman DR, Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 2003 19 71 82
4. Koltsova EK, Hedrick CC, Ley K, Myeloid cells in atherosclerosis: a delicate balance of anti-inflammatory and proinflammatory mechanisms. Curr Opin Lipidol 2013 24 371 380. doi: 10.1097/MOL.0b013e328363d298
5. Soehnlein O, Drechsler M, Hristov M, Weber C, Functional alterations of myeloid cell subsets in hyperlipidaemia: relevance for atherosclerosis. J Cell Mol Med 2009 13 4293 4303. doi: 10.1111/j.1582-4934.2009.00965.x
6. Johannessen M, Møller S, Hansen T, Moens U, Van Ghelue M, The multifunctional roles of the four-And-A-half-LIM only protein FHL2. Cell Mol Life Sci 2006 63 268 284. doi: 10.1007/s00018-005-5438-z
7. Chen D, Xu W, Bales E, Colmenares C, Conacci-Sorrell M, IshII S, Stavnezer E, Campisi J, Fisher DE, Ben-Ze'ev A, Medrano EE, SKI activates Wnt/beta-catenin signaling in human melanoma. Cancer Res 2003 63 6626 6634
8. Morlon A, Sassone-Corsi P, The LIM-only protein FHL2 is a serum-inducible transcriptional coactivator of AP-1. Proc Natl Acad Sci U S A 2003 100 3977 3982. doi: 10.1073/pnas.0735923100
9. Müller JM, Isele U, Metzger E, Rempel A, Moser M, Pscherer A, Breyer T, Holubarsch C, Buettner R, Schüle R, FHL2, a novel tissue-specific coactivator of the androgen receptor. EMBO J 2000 19 359 369. doi: 10.1093/emboj/19.3.359
10. Purcell NH, Darwis D, Bueno OF, Müller JM, Schüle R, Molkentin JD, Extracellular signal-regulated kinase 2 interacts with and is negatively regulated by the LIM-only protein FHL2 in cardiomyocytes. Mol Cell Biol 2004 24 1081 1095
11. Samson T, Smyth N, Janetzky S, Wendler O, Müller JM, Schüle R, von der Mark H, von der Mark K, Wixler V, The LIM-only proteins FHL2 and FHL3 interact with alpha-And beta-subunits of the muscle alpha7beta1 integrin receptor. J Biol Chem 2004 279 28641 28652. doi: 10.1074/jbc.M312894200
12. Wei Y, Renard CA, Labalette C, Wu Y, Lévy L, Neuveut C, Prieur X, Flajolet M, Prigent S, Buendia MA, Identification of the LIM protein FHL2 as a coactivator of beta-catenin. J Biol Chem 2003 278 5188 5194. doi: 10.1074/jbc.M207216200
13. Chan KK, Tsui SK, Lee SM, Luk SC, Liew CC, Fung KP, Waye MM, Lee CY, Molecular cloning and characterization of FHL2, a novel LIM domain protein preferentially expressed in human heart. Gene 1998 210 345 350
14. Lange S, Auerbach D, McLoughlin P, Perriard E, Schäfer BW, Perriard JC, Ehler E, Subcellular targeting of metabolic enzymes to titin in heart muscle may be mediated by DRAL/FHL-2. J Cell Sci 2002 115 Pt 24 4925 4936
15. Morgan MJ, Madgwick AJ, Slim defines a novel family of LIM-proteins expressed in skeletal muscle. Biochem Biophys Res Commun 1996 225 632 638. doi: 10.1006/bbrc.1996.1222
16. Hayashi H, Nakagami H, Takami Y, Koriyama H, Mori M, Tamai K, Sun J, Nagao K, Morishita R, Kaneda Y, FHL-2 suppresses VEGF-induced phosphatidylinositol 3-kinase/Akt activation via interaction with sphingosine kinase-1. Arterioscler Thromb Vasc Biol 2009 29 909 914. doi: 10.1161/ATVBAHA.108.178541
17. Neuman NA, Ma S, Schnitzler GR, Zhu Y, Lagna G, Hata A, The four-And-A-half LIM domain protein 2 regulates vascular smooth muscle phenotype and vascular tone. J Biol Chem 2009 284 13202 13212. doi: 10.1074/jbc.M900282200
18. Ebrahimian T, Arfa O, Simeone S, Lemarié CA, Lehoux S, Wassmann S, Inhibition of four-And-A-half LIM domain protein-2 increases survival, migratory capacity, and paracrine function of human early outgrowth cells through activation of the sphingosine kinase-1 pathway: implications for endothelial regeneration. Circ Res 2014 114 114 123. doi: 10.1161/CIRCRESAHA.113.301954
19. Sawai CM, Sisirak V, Ghosh HS, Hou EZ, Ceribelli M, Staudt LM, Reizis B, Transcription factor Runx2 controls the development and migration of plasmacytoid dendritic cells. J Exp Med 2013 210 2151 2159. doi: 10.1084/jem.20130443
20. König K, Diehl L, Rommerscheidt-Fuss U, Golletz C, Quast T, Kahl P, Kolanus W, Knolle P, Buettner R, Heukamp LC, Four-And-A-half LIM domain protein 2 is a novel regulator of sphingosine 1-phosphate receptor 1 in CCL19-induced dendritic cell migration. J Immunol 2010 185 1466 1475. doi: 10.4049/jimmunol.0903449
21. Alnajar A, Nordhoff C, Schied T, Chiquet-Ehrismann R, Loser K, Vogl T, Ludwig S, Wixler V, The LIM-only protein FHL2 attenuates lung inflammation during bleomycin-induced fibrosis. PLoS One 2013 8 e81356. doi: 10.1371/journal.pone.0081356
22. Chu PH, Yeh HI, Wu HH, Hong RC, Shiu TF, Yang CM, Deletion of the FHL2 gene attenuates the formation of atherosclerotic lesions after a cholesterol-enriched diet. Life Sci 2010 86 365 371. doi: 10.1016/j.lfs.2010.01.007
23. Chu PH, Ruiz-Lozano P, Zhou Q, Cai C, Chen J, Expression patterns of FHL/SLIM family members suggest important functional roles in skeletal muscle and cardiovascular system. Mech Dev 2000 95 259 265
24. Dahan J, Nouët Y, Jouvion G, LIM-only protein FHL2 activates NF-κB signaling in the control of liver regeneration and hepatocarcinogenesis. Mol Cell Biol 2013 33 3299 3308. doi: 10.1128/MCB.00105-13
25. Park J, Will C, Martin B, Gullotti L, Friedrichs N, Buettner R, Schneider H, Ludwig S, Wixler V, Deficiency in the LIM-only protein FHL2 impairs assembly of extracellular matrix proteins. FASEB J 2008 22 2508 2520. doi: 10.1096/fj.07-095521
26. Kirfel J, Pantelis D, Kabba M, Kahl P, Röper A, Kalff JC, Buettner R, Impaired intestinal wound healing in Fhl2-deficient mice is due to disturbed collagen metabolism. Exp Cell Res 2008 314 3684 3691. doi: 10.1016/j.yexcr.2008.09.023
27. Wixler V, Hirner S, Müller JM, Gullotti L, Will C, Kirfel J, Günther T, Schneider H, Bosserhoff A, Schorle H, Park J, Schüle R, Buettner R, Deficiency in the LIM-only protein Fhl2 impairs skin wound healing. J Cell Biol 2007 177 163 172. doi: 10.1083/jcb.200606043
28. Kurakula K, Vos M, Otermin Rubio I, Marinković G, Buettner R, Heukamp LC, Stap J, de Waard V, van Tiel CM, de Vries CJ, The LIM-only protein FHL2 reduces vascular lesion formation involving inhibition of proliferation and migration of smooth muscle cells. PLoS One 2014 9 e94931. doi: 10.1371/journal.pone.0094931
29. Allahverdian S, Pannu PS, Francis GA, Contribution of monocyte-derived macrophages and smooth muscle cells to arterial foam cell formation. Cardiovasc Res 2012 95 165 172. doi: 10.1093/cvr/cvs094
30. Huang PH, Chen CY, Lin CP, Wang CH, Tsai HY, Lo WY, Leu HB, Chen JW, Lin SJ, Chu PH, Deletion of FHL2 gene impaired ischemia-induced blood flow recovery by modulating circulating proangiogenic cells. Arterioscler Thromb Vasc Biol 2013 33 709 717. doi: 10.1161/ATVBAHA.112.300318
31. Qiao L, Wang Y, Pang R, Wang J, Dai Y, Ma J, Gu Q, Li Z, Zhang Y, Zou B, Lan HY, Wong BC, Oncogene functions of FHL2 are independent from NF-kappaBIalpha in gastrointestinal cancer. Pathol Oncol Res 2009 15 31 36. doi: 10.1007/s12253-008-9085-1
32. Wong CH, Mak GW, Li MS, Tsui SK, The LIM-only protein FHL2 regulates interleukin-6 expression through p38 MAPK mediated NF-κB pathway in muscle cells. Cytokine 2012 59 286 293. doi: 10.1016/j.cyto.2012.04.044
33. Fimia GM, De Cesare D, Sassone-Corsi P, A family of LIM-only transcriptional coactivators: tissue-specific expression and selective activation of CREB and CREM. Mol Cell Biol 2000 20 8613 8622
34. Gabriel B, Mildenberger S, Weisser CW, Metzger E, Gitsch G, Schüle R, Müller JM, Focal adhesion kinase interacts with the transcriptional coactivator FHL2 and both are overexpressed in epithelial ovarian cancer. Anticancer Res 2004 24 2B 921 927
35. Wixler V, Geerts D, Laplantine E, Westhoff D, Smyth N, Aumailley M, Sonnenberg A, Paulsson M, The LIM-only protein DRAL/FHL2 binds to the cytoplasmic domain of several alpha and beta integrin chains and is recruited to adhesion complexes. J Biol Chem 2000 275 33669 33678. doi: 10.1074/jbc.M002519200
36. Hanna RN, Carlin LM, Hubbeling HG, Nackiewicz D, Green AM, Punt JA, Geissmann F, Hedrick CC, The transcription factor NR4A1 (Nur77) controls bone marrow differentiation and the survival of Ly6C-monocytes. Nat Immunol 2011 12 778 785. doi: 10.1038/ni.2063
37. Hanna RN, Shaked I, Hubbeling HG, Punt JA, Wu R, Herrley E, Zaugg C, Pei H, Geissmann F, Ley K, Hedrick CC, NR4A1 (Nur77) deletion polarizes macrophages toward an inflammatory phenotype and increases atherosclerosis. Circ Res 2012 110 416 427. doi: 10.1161/CIRCRESAHA.111.253377
38. Bonta PI, van Tiel CM, Vos M, Pols TW, van Thienen JV, Ferreira V, Arkenbout EK, Seppen J, Spek CA, van der Poll T, Pannekoek H, de Vries CJ, Nuclear receptors Nur77, Nurr1, and NOR-1 expressed in atherosclerotic lesion macrophages reduce lipid loading and inflammatory responses. Arterioscler Thromb Vasc Biol 2006 26 2288 2294. doi: 10.1161/01.ATV.0000238346.84458.5d
39. Kurakula K, van der Wal E, Geerts D, van Tiel CM, de Vries CJ, FHL2 protein is a novel co-repressor of nuclear receptor Nur77. J Biol Chem 2011 286 44336 44343. doi: 10.1074/jbc.M111.308999
40. Lahoute C, Herbin O, Mallat Z, Tedgui A, Adaptive immunity in atherosclerosis: mechanisms and future therapeutic targets. Nat Rev Cardiol 2011 8 348 358. doi: 10.1038/nrcardio.2011.62